OTLK Earnings Date: Dec 18, 2026 (Estimated) — Outlook Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Updated
When is OTLK's next earnings date?
Outlook Therapeutics, Inc. Common Stock (OTLK) is expected to report Q4 2026 earnings on Friday, December 18, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $2.4M.
How did OTLK do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q3 2026), Outlook Therapeutics, Inc. Common Stock posted EPS of -$0.09 versus the -$0.08 estimate, a miss of 12.5%. Revenue was $9,000 against a $966,667 estimate. The stock's 1-day post-earnings move was -14.9%.
How much does OTLK stock move after earnings?
OTLK beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.9% (up or down) in the day after earnings.
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q3 2026 | -0.08 | -0.09 | -12.50% | $9,000 | ❌ Miss | -14.90% | -23.91% | -28.23% |
| 2026-05-15 | Q2 2026 | -0.12 | -0.16 | -33.33% | $128,000 | ❌ Miss | +0.48% | +35.86% | +588.29% |
| 2026-02-17 | Q1 2026 | -0.17 | -0.22 | -29.41% | $-1.2M | ❌ Miss | -13.82% | -18.37% | -19.24% |
| 2025-12-19 | Q4 2025 | -0.24 | -0.19 | +20.83% | $-91,787 | ✅ Beat | -2.90% | -12.08% | -75.56% |
| 2025-08-14 | Q3 2025 | -0.40 | -0.44 | -10.00% | $1.5M | ❌ Miss | +14.08% | +12.21% | -51.17% |
| 2025-02-14 | Q1 2025 | -0.52 | -0.89 | -71.15% | $0 | ❌ Miss | +1.63% | -15.22% | -16.30% |
| 2024-12-27 | Q4 2024 | -0.85 | -0.94 | -10.59% | $0 | ❌ Miss | +18.24% | +31.76% | +17.06% |
| 2024-08-14 | Q3 2024 | -1.01 | -0.83 | +17.82% | $0 | ✅ Beat | -5.29% | -8.39% | -16.26% |
Showing last 8 quarters.